Design Therapeutics (DSGN) Common Equity (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Common Equity of $201.9 million for Q2 2026, down 5.25% year-over-year from $213.0 million in Q2 2025, and down 7.43% on a QoQ basis from $218.1 million in Q1 2026.
Design Therapeutics (DSGN) Common Equity (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Common Equity for 7 years, with the latest figure at $201.9 million in Q2 2026.
- Common Equity for Q2 2026 came in at $201.9 million, down 5.25% year-over-year; the trailing twelve-month figure through Jun 2026 was $201.9 million (down 5.25% YoY), and the FY2025 annual result was $212.5 million, down 12.22% from the prior year.
- Common Equity slipped to $201.9 million in Q2 2026, from $218.1 million in the prior quarter.
- Over five years, Common Equity peaked at $370.3 million in Q1 2022 and troughed at $199.7 million in Q3 2025.
- A 5-year average of $270.4 million and a median of $265.4 million in 2024 frame the typical range for Common Equity.
- The widest annual swing landed in 2025, when Common Equity declined 20.89%; it then retreated 4.33% in 2026.
- A 5-year view of Common Equity shows it stood at $327.3 million in 2022, then decreased by 15.16% to $277.7 million in 2023, then decreased by 12.82% to $242.1 million in 2024, then retreated by 12.22% to $212.5 million in 2025, then declined by 5.01% to $201.9 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $201.9 million in Q2 2026, $218.1 million in Q1 2026, and $212.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 201.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 201.86 Mn |
| Mar 31, 2026 | 218.05 Mn |
| Dec 31, 2025 | 212.50 Mn |
| Sep 30, 2025 | 199.72 Mn |
| Jun 30, 2025 | 213.04 Mn |
| Mar 31, 2025 | 227.92 Mn |
| Dec 31, 2024 | 242.10 Mn |
| Sep 30, 2024 | 252.45 Mn |
| Jun 30, 2024 | 261.24 Mn |
| Mar 31, 2024 | 269.56 Mn |
| Dec 31, 2023 | 277.69 Mn |
| Sep 30, 2023 | 284.96 Mn |
| Jun 30, 2023 | 296.80 Mn |
| Mar 31, 2023 | 312.82 Mn |
| Dec 31, 2022 | 327.31 Mn |
| Sep 30, 2022 | 340.94 Mn |
| Jun 30, 2022 | 357.16 Mn |
| Mar 31, 2022 | 370.31 Mn |
| Dec 31, 2021 | 382.13 Mn |
| Sep 30, 2021 | 391.56 Mn |